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A novel approach for cancer immunotherapy is to use gene therapy to reprogram patient or donor T-
cells to target and kill tumor cells. T-cells can be engineered to express a high affinity T-cell receptor 
(TCR) that recognizes a tumor-specific antigen. Since tumors are derived from normal tissue, most 
of the tumor targets for T-cell based immunotherapy are self-antigens. These tumor antigens are 
expressed at high levels in cancers, but are found at low levels in select cell types in the adult. 
During T-cell development in the thymus, T-cells are sorted by their relative ability to recognize and 
react to self and non-self antigens to prepare the immune system to mount a response to any foreign 
invader while preventing autoimmunity. T-cells that bind weakly to self-antigens are allowed to 
survive and undergo further development to fight foreign invaders, while T-cells that bind strongly to 
self-antigens would mount an autoimmune response and are therefore eliminated by the immune 
system. This central tolerance mechanism limits the ability to isolate naturally occurring T-cells that 
could bind tumor antigens with high affinity and effectively eliminate tumor cells. 
 To circumvent this problem, T-cell receptors (TCRs) can be engineered in vitro to improve binding 
affinity to tumor antigens and promote more potent killing of tumor cells. However, tumor-specific 
TCRs that have been affinity-enhanced beyond the limits of thymic selection have the potential to 
elicit autoimmunity when used in TCR gene therapy. Alternatively, thymic selection may be 
overprotective and TCRs with high binding affinity to tumor/self-antigens could potentially be 
tolerated in the periphery outside of the thymus. To address this hypothesis, postdoctoral fellow Dr. 
Thomas Schmitt and researchers in the laboratory of Dr. Philip Greenberg (Clinical Research 
Division) used a mouse model to assess efficacy and safety of gene therapy using enhanced-affinity 
TCRs for two separate tumor antigens. 
 Wilms’ tumor antigen 1 (WT1) is a transcription factor that is detected only at low levels in a subset 
of normal cell types, but is over-expressed 10- to 1,000-fold in many solid tumor and leukemia cells. 
The team isolated a WT1-reactive TCR from T-cells of mice and cloned the TCR into a retroviral 
vector for gene therapy. They then mutated this WT1-specific TCR to find variants with higher 
binding affinity using a saturation mutagenesis screen. The researchers identified two of the 
engineered TCRs that appeared to bind with higher affinity to WT1 in vitro. To test if increased 
binding affinity translates to enhanced T-cell function, the TCR variants were transduced into T-cell 
lines and tested for T-cell activation against WT1 antigen ex vivo. The mutant TCR with the highest 
binding affinity had the highest functional activity as measured by T-cell expression and release of 
cytokines (see figure). 
To replicate the conditions of how human TCR gene therapy is performed, cytotoxic CD8+ T-cells 
were transduced with the different WT1-specific TCRs, expanded ex vivo, and injected into mice. T-
cells expressing the enhanced-affinity TCRs were not preferentially selected for or against in the  
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peripheral blood, suggesting they were not responding to WT1 or cross-reactive self antigens. 
Importantly, enhanced-affinity WT1-specific T-cells did not target normal tissues or elicit 
autoimmunity, even in tissues that express low levels of WT1 expression. The researchers then 
asked if tissue damage increased after inflammatory conditions were induced by an external 
bacterial pathogen. Modified T-cells were transferred into mice infected with a strain of the 
bacteria Listeria monocytogenes engineered to express WT1 to activate and expand the WT1-
reactive T-cells; and, again, the enhanced-affinity TCRs did not direct the T-cells to target normal 
tissues. 
Schmitt et al. also asked if the enhanced-affinity TCR genes would be selected against during 
normal T-cell development in the thymus. Hematopoietic stem cells were transduced with the TCR 
genes, and the T-cell progenitors that developed from these cells displayed negative selection with 
reduced function against the WT1 antigen. This study provides support for the hypothesis that 
thymic selection may be overprotective and TCRs with high binding affinity to tumor/self-antigens 
could potentially be tolerated in the periphery. 
To further support the safety of gene therapy with enhanced-affinity TCRs, the authors performed 
identical experiments with TCRs specific for the tumor antigen mesothelin. The researchers showed 
that for both WT1 and mesothelin, the enhanced-affinity TCRs can be expressed in T-cells and 
transferred in vivo without any signs of autoimmunity. In a previous publication, the Greenberg 
laboratory demonstrated clinical efficacy of using adoptive T-cell therapy with CD8+ T-cells reactive 
to WT1 in human patients with high-risk post-transplant leukemias  (Chapuis AG et al., 2013). 
"Future studies will focus on testing enhanced-affinity variants of this TCR in a humanized mouse 
model of TCR gene therapy targeting WT1," according to Drs. Schmitt and Greenberg. If confirmed 
to be safe, this approach could increase the anti-tumor activity of adoptive T-cell therapy to treat 
high-risk cancer patients. 
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Image provided by Thomas Schmitt 
Mutation of a T-cell receptor (TCR) confers a higher binding 
affinity to the tumor antigen WT1, increasing T-cell activity 
against WT1-overexpressing cells without eliciting autoimmunity 
in a mouse model. A) Schematic of the amino acid mutations in 
the WT1-specific TCR alpha chain (3D) that increase binding 
affinity to WT1. B) WT1 binding affinity is increased for the TCR 
mutants (NYH and PYY) versus the wild-type TCR sequence as 
measured by flow cytometry. C) T-cell activation, measured by 
interferon (IFN) expression, is increased for the high affinity TCR 
transduced T-cells (PYY blue, NYH red, 3D wild-type green). 
 
